Enlargement and multinucleation of U937 leukemia and MCF7 breast carcinoma cells by antineoplastic agents to enhance sensitivity to low frequency ultrasound and to DNA-directed anticancer agents

Anticancer Research

Volumn 35, Issue 1, 2015, Pages 65-76

  Trendowski, Matthew ^a   Wong, Victoria ^a   Yu, Guowu ^a   Fondy, Thomas P ^a  

^a SYRACUSE UNIVERSITY   (United States)

Author keywords

Breast carcinoma; Cell enlargement; Chemotherapy; Cytochalasin B; Cytoskeletal directed agents; Leukemia; Nucleic acid directed agents

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHALASIN B; DNA; DOXORUBICIN; MITOMYCIN; PACLITAXEL; VINCRISTINE; CYTARABINE; METHOTREXATE; RADIOSENSITIZING AGENT;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL LINE; CELL ENLARGEMENT; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LOW FREQUENCY ULTRASOUND; MCF 7 CELL LINE; U937 CELL LINE; ULTRASOUND; CELL NUCLEUS; DRUG EFFECTS; DRUG SCREENING; LEUKEMIA; SOUND;

ANTINEOPLASTIC AGENTS; CELL ENLARGEMENT; CELL NUCLEUS; CYTARABINE; CYTOCHALASIN B; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; LEUKEMIA; MCF-7 CELLS; METHOTREXATE; MITOMYCIN; RADIATION-SENSITIZING AGENTS; SOUND;

EID: 84920456497     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Trendowski M: The promise of sonodynamic therapy. Cancer Metastasis Rev 33: 143-160, 2014.
2. Cooper JA: Effects of cytochalasin and phalloidin on actin. J Cell Biol 105: 1473-1478, 1987.
3. Painter RG, Whisenand J and McIntosh AT: Effects of cytochalasin B on actin and myosin association with particle binding sites in mouse macrophages: implications with regard to the mechanism of action of the cytochalasins. J Cell Biol 91: 373-384, 1981.
4. Yahara I, Harada F, Sekita S, Yoshihira Y and Natori S: Correlation between effects of 24 different cytochalasins on cellular structures and cellular events and those on actin in vitro. J Cell Biol 92: 69-78, 1982.
5. Trendowski M, Yu G, Wong V, Acquafondata C, Christen T and Fondy TP: The real deal: using cytochalasin B in sonodynamic therapy to preferentially damage leukemia cells. Anticancer Res 34: 2195-2202, 2014.
6. Rosenthal I, Sostaric JZ and Riesz P: Sonodynamic Therapy -A Review of the Synergistic Effects of Drugs and Ultrasound. Ultrasonics Sonochemistry 11: 349-363, 2004.
7. Bai W, Shen E and Hu B: Induction of the Apoptosis of Cancer Cell by Sonodynamic Therapy: A Review. Chinese Journal of Cancer Research 24: 368-373, 2012.
8. Kuroki M, Hachimine K, Abe H, Shibaguchi H, Kuroki M, Maekawa S, Yanagisawa J, Kinugasa T, Tanaka T and Yamashita Y: Sonodynamic therapy of cancer using novel sonosensitizers. Anticancer Res 27: 3673-3677, 2007.
9. Mitragotri S: Healing sound: the use of ultrasound in drug delivery and other therapeutic applications. Nat Rev Drug Discov 4: 255-260, 2005.
10. Weinberg RA: The biology of cancer, 2nd edition. Garland Science 2013.
11. Lagneaux L, Cordemans de Meulenaer E, Delforge A, Dejeneffe M, Massy M, Moerman C, Hannecart B, Canivet Y, Lepeltier M and Bron D: Ultrasonic Low-Energy Treatment: A Novel Approach to Induce Apoptosis in Human Leukemic Cells. Experimental Hematology 30: 1293-1301, 2002.
12. Honda H, Kondo T, Zhao Q, Feril LB Jr. and Kitatgawa H: Role of Intracellular Calcium Ions and Reactive Oxygen Species in Apoptosis Induced by Ultrasound. Ultrasound in Medicine and Biology 30: 683-692, 2004.
13. Bousquet PF, Paulsen LA, Fondy C, Lipski KM, Loucy KJ and Fondy TP: Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma. Cancer Res 50: 1431-1439, 1990.
14. Steiner MR, Altenburg B, Richards CS, Dudley JP, Medina D and Butel JS: Differential response of cultured mouse mammary cells of varying tumorigenicity to cytochalasin B. Cancer Res 38: 2719-2721, 1978.
15. Medina D, Oborn CJ and Asch BB: Distinction between preneopastic and neoplastic mammary cell populations in vitro by cytochalasin B-induced multinucleation. Cancer Res 40: 329-333, 1980.
16. Bogyo D, Fondy SR, Finster L, Fondy C, Patil S and Fondy TP: Cytochalasin-B-induced immunosuppression of murine allogeneic anti-tumor response and the effect of recombinant human interleukin-2. Cancer Immunol Immunother 32: 400-405, 1991.
17. Chao JI and Liu HF: The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol 69: 154-164, 2006.
18. Kolber MA and Hill P: Vincristine potentiates cytochalasin Binduced DNA fragmentation in vitro. Cancer Chemother Pharmacol 30: 286-290, 1992.
19. Chhikara BS and Parang K: Development of cytarabine prodrugs and delivery systems for leukemia treatment. Expert Opinion on Drug Delivery 7: 1399-1414, 2010.
20. Tacar O, Sriamornsak P and Dass CR: Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. Journal of Pharmacy and Pharmacology 65: 157-170, 2013.
21. Liang L, Xie S, Jiang L, Jin H, Li S and Liu J: The combined effects of hematoporphyrin monomethyl ether-SDT and doxorubicin on the proliferation of QBC939 cell lines. Ultrasound in Medicine & Biology 39: 146-160, 2013.
22. Tomasz M: Mitomycin C: small, fast and deadly (but very selective). Chemistry and Biology 2: 575-579, 1995.
23. Alderden RA, Hall MD and Hambley TW: The Discovery and Development of Cisplatin. J Chem Ed 83: 728-724, 2006.
24. Goodsell DS: The molecular perspective: methotrexate. Oncologist 4: 340-341, 1999.
25. Skorpikova J, Dolnikova M, Hrazdira I and Janisch R: Changes in microtubules and microfilaments due to a combined effect of ultrasound and cytostatics in HeLa cells. Folia Biologica 47: 143-147, 2001.
26. Burger RM, Peisach J and Horwitz SB: Mechanism of bleomycin action: in vitro studies. Life Sci 28: 715-727, 1981.
27. Hecht SM: Bleomycin: new perspectives on the mechanism of action. J Nat Prod 63: 158-168, 2000.
28. Egyhazi S, Bergh J, Hansson J, Karran P and Ringborg U: Carmustine-induced toxicity, DNA crosslinking and O6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur J Cancer 27: 1658-1662, 1991.
29. Ugurel S, Paschen A and Becker JC: Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent. J Invest Dermatol 133: 289-292, 2013.
30. Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
31. Groninger E, Meeuwsen-De Boer GJ, De Graaf SS, Kamps WA and De Bont ES: Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrialcontrolled pathway regulated by reactive oxygen species? Int J Oncol 21: 1339-1345, 2002.
32. Conway RM, Madigan MC, Billson FA and Penfold PL: Vincristine-and cisplatin-induced apoptosis in human retinoblastoma. Potentiation by sodium butyrate. Eur J Cancer 34: 1741-1748, 1998.
33. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL: Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18: 3509-3517, 1998.
34. Bhattacharyya B, Panda D, Gupta S and Banerjee M: Antimitotic activity of colchicine and the structural basis for its interaction with tubulin. Med Res Rev 28: 155-183, 2008.
35. Bharadwaj R and Yu H: The spindle checkpoint, aneuploidy, and cancer. Oncogene 23: 2016-2027, 2004.
36. Gessner PK: Isobolographic analysis of interactions: an update on applications and utility. Toxicology 105: 161-179, 1995.
37. Berridge MV, Herst PM and Tan AS: Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152, 2005.
38. O'Neill FJ: Selective destruction of cultured tumor cells with uncontrolled nuclear division by cytochalasin B and cytosine arabinoside. Cancer Res 35: 3111-3115, 1975.
39. Trendowski M, Wong V, Wellington K, Hatfield S and Fondy TP. Tolerated doses in zebrafish of cytochalasins and jasplakinolide for comparison with tolerated doses in mice in the evaluation of pre-clinical activity of microfilament-directed agents in tumor model systems in vivo. In Vivo In press, 2014.
40. Goertz DE, Todorova M, Mortazavi O, Agache V, Chen B, Karshafian R and Hynynen K: Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles. PLoS One 7: e52307, 2012.
41. Su X, Wang P, Wang X, Cao B, Li L and Liu Q: Apoptosis of U937 cells induced by hematoporphyrin monomethyl ethermediated sonodynamic action. Cancer Biotherapy and Radiopharmaceuticals 28: 207-217, 2013.
42. Tinkov S, Coester C, Serba S, Geis NA, Katus HA, Winter G and Bekeredjian R: New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: In vivo characterization. Journal of Controlled Release 148: 368-372, 2010.
43. Nie F, Xu HX, Lu MD, Wang Y and Tang Q: Anti-angiogenic gene Therapy for hepatocellular carcinoma mediated by microbubble-enhanced ultrasound exposure: An in vivo experimental study. Journal of Drug Targeting 16: 389-395, 2008.